Skip to main content
SpringerLink
Log in

Psychiatric Diseases in Children and Adolescents

  • Chapter
  • First Online:
Pediatric Pharmacotherapy

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 261))

Abstract

Pharmacotherapy of psychiatric illnesses in children and adolescents has grown significantly over the last few decades. However, the body of research examining pharmacological treatments for psychiatric illnesses is much smaller in children and adolescents than it is in adults. As most treatments for psychiatric disorders are more effective if started early in the course of illness, treatment options for youth are especially important in order to ensure better treatment outcomes. This chapter discusses currently approved medications to treat psychiatric disorders in children and adolescents. Research on medications that may be effective treatments but are not yet FDA approved is also discussed. The medications are broken down into major categories used in youth with psychiatric disorders including antidepressants, mood stabilizers, ADHD medications, and antipsychotics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Alderman J, Wolkow R, Chung M, Johnston HF (1998) Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 37(4):386–394

    Article  CAS  PubMed  Google Scholar 

  • American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Publication, Philadelphia

    Book  Google Scholar 

  • Amor LB (2012) Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord 138:S22–S30

    Article  PubMed  CAS  Google Scholar 

  • Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58(1):19–36

    Article  CAS  PubMed  Google Scholar 

  • Atkinson SD, Prakash A, Zhang Q, Pangallo BA, Bangs ME, Emslie GJ, March JS (2014) A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 24(4):180–189

    Article  CAS  PubMed  Google Scholar 

  • Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL (2018) Desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 28(1):55–65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barzman DH, DelBello MP, Kowatch RA, Warner J, Rofey D, Stanford K et al (2005) Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 15(6):931–937

    Article  PubMed  Google Scholar 

  • Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C (2006) An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 16(1–2):59–75

    Article  PubMed  Google Scholar 

  • Bernstein GA, Borchardt CM, Perwien AR, Crosby RD, Kushner MG, Thuras PD, Last CG (2000) Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 39(3):276–283

    Article  CAS  PubMed  Google Scholar 

  • Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M et al (2003) Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42(4):415–423

    Article  PubMed  Google Scholar 

  • Bradley C (1937) The behavior of children receiving benzedrine. Am J Psychiatry 94(3):577–585

    Article  Google Scholar 

  • Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M et al (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 299(8):901–913

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brown KA, Samuel S, Patel DR (2018) Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. Transl Pediatr 7(1):36

    Article  PubMed  PubMed Central  Google Scholar 

  • Campo JV, Perel J, Lucas A, Bridge J, Ehmann M, Kalas C et al (2004) Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. J Am Acad Child Adolesc Psychiatry 43(10):1234–1242

    Article  PubMed  Google Scholar 

  • Chang K, Saxena K, Howe M (2006) An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 45(3):298–304

    Article  PubMed  Google Scholar 

  • Cheng JY, Chen RY, Ko JS, Ng EM (2007) Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents – meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 194(2):197–209

    Article  CAS  Google Scholar 

  • Cheung A, Sacks D, Dewa CS, Pong J, Levitt A (2008) Pediatric prescribing practices and the FDA black-box warning on antidepressants. J Dev Behav Pediatr 29(3):213–215

    Article  PubMed  Google Scholar 

  • Clark DB, Birmaher B, Axelson D, Monk K, Kalas C, Ehmann M et al (2005) Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 44(12):1263–1270

    Article  PubMed  Google Scholar 

  • Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B, Sherrill JT et al (2010) Child/adolescent anxiety multimodal study (CAMS): rationale, design, and methods. Child Adolesc Psychiatry Ment Health 4(1):1

    Article  PubMed  PubMed Central  Google Scholar 

  • Conners CK, Eisenberg L, Barcai A (1967) Effect of dextroamphetamine on children: studies on subjects with learning disabilities and school behavior problems. Arch Gen Psychiatry 17(4):478–485

    Article  CAS  PubMed  Google Scholar 

  • Conners CK, Rothschild G, Eisenberg L, Schwartz LS, Robinson E (1969) Dextroamphetamine sulfate in children with learning disorders children with learning disorders: effects on perception, learning and achievement. Arch Gen Psychiatry 21(2):182–190

    Article  CAS  PubMed  Google Scholar 

  • Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, Messig M (2001) Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 40(10):1175–1181

    Article  CAS  PubMed  Google Scholar 

  • DelBello MP, Kowatch RA, Warner J, Schwiers ML, Rappaport KB, Daniels JP et al (2002) Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol 12(4):323–330

    Article  PubMed  Google Scholar 

  • Delbello MP, Findling RL, Kushner S, Wang D, Olson WH, Capece JA et al (2005) A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44(6):539–547

    Article  PubMed  Google Scholar 

  • DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M et al (2009) A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11(5):483–493

    Article  CAS  PubMed  Google Scholar 

  • Dopheide JA (2006) Recognizing and treating depression in children and adolescents. Am J Health Syst Pharm 63(3):233–243

    Article  PubMed  Google Scholar 

  • Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54(11):1031–1037

    Article  CAS  PubMed  Google Scholar 

  • Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E et al (2002) Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41(10):1205–1215

    Article  PubMed  Google Scholar 

  • Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ et al (2006) Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 45(6):709–719

    Article  PubMed  Google Scholar 

  • Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y (2007) Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 46(4):479–488

    Article  PubMed  Google Scholar 

  • Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S (2009) Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 48(7):721–729

    Article  PubMed  Google Scholar 

  • Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71(6):754

    Article  PubMed  Google Scholar 

  • Findling RL, Ginsberg LD (2014) The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 10:1589

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Findling RL, McNamara NK, Gracious BL, ORiordan MA, Reed MD, Demeter C, Blumer JL (2004) Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14(2):287–294

    Article  PubMed  Google Scholar 

  • Findling RL, Mcnamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, Calabrese JR (2005) Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 44(5):409–417

    Article  PubMed  Google Scholar 

  • Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM et al (2010) Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49(6):583–594

    PubMed  PubMed Central  Google Scholar 

  • Findling RL, Youngstrom EA, McNamara NK, Stansbrey RJ, Wynbrandt JL, Adegbite C et al (2012) Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry 73(1):57

    Article  CAS  PubMed  Google Scholar 

  • Findling RL, Çavuş I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, DelBello MP (2013a) Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 23(8):545–557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Findling RL, Correll CU, Nyilas M, Forbes RA, McQuade RD, Jin N et al (2013b) Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 15(2):138–149

    Article  CAS  PubMed  Google Scholar 

  • Findling RL, Robb A, Bose A (2013c) Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. J Child Adolesc Psychopharmacol 23(7):468–480

    Article  PubMed  PubMed Central  Google Scholar 

  • Findling RL, Pathak S, Earley WR, Liu S, DelBello MP (2014) Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 24(6):325–335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Findling RL, Chang K, Robb A, Foster VJ, Horrigan J, Krishen A et al (2015a) Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 54(12):1020–1031

    Article  PubMed  Google Scholar 

  • Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R et al (2015b) Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics 136(5):885

    Article  PubMed  PubMed Central  Google Scholar 

  • Garcia AM, Sapyta JJ, Moore PS, Freeman JB, Franklin ME, March JS, Foa EB (2010) Predictors and moderators of treatment outcome in the pediatric obsessive compulsive treatment study (POTS I). J Am Acad Child Adolesc Psychiatry 49(10):1024–1033

    Article  PubMed  PubMed Central  Google Scholar 

  • Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura ROY, Kluszynski S et al (2001) Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40(7):773–779

    Article  CAS  PubMed  Google Scholar 

  • Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT et al (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 69(5):515–528

    Article  CAS  PubMed  Google Scholar 

  • Ghanizadeh A, Sahraeizadeh A, Berk M (2014) A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 45(2):185–192

    Article  PubMed  Google Scholar 

  • Gillberg C (2001) Epidemiology of early onset schizophrenia. In: Remschmidt H (ed) Schizophrenia in children and adolescents. Cambridge University Press, Cambridge, pp 43–59

    Google Scholar 

  • Gittelman-Klein R, Klein DF (1971) Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 25(3):204–207

    Article  Google Scholar 

  • Golubchik P, Sever J, Weizman A (2011) Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol 34(6):216–219

    Article  CAS  PubMed  Google Scholar 

  • Gothelf D, Rubinstein M, Shemesh E, Miller O, Farbstein I, Klein A et al (2005) Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry 44(12):1258–1262

    Article  PubMed  Google Scholar 

  • Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16(5):541–548

    Article  PubMed  Google Scholar 

  • Isolan L, Pheula G, Salum GA Jr, Oswald S, Rohde LA, Manfro GG (2007) An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 17(6):751–760

    Article  PubMed  Google Scholar 

  • Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Georgiopoulos A et al (2010) A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adolesc Psychopharmacol 20(1):7–14

    Article  PubMed  Google Scholar 

  • Kachko L, Ben Ami S, Liberman A, Birk E, Kronenberg S (2011) Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid ‘reactive depression’ in an adolescent. Pain Res Manag 16(6):457–459

    Article  PubMed  PubMed Central  Google Scholar 

  • Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22(5):455–460

    Article  CAS  PubMed  Google Scholar 

  • Klein RG, Koplewicz HS, Kanner A (1992) Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 31(1):21–28

    Article  CAS  PubMed  Google Scholar 

  • Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, Khayrallah M (2011) Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 127(6):e1406

    Article  PubMed  PubMed Central  Google Scholar 

  • Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis M et al (2000) Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 39(6):713–720

    Article  CAS  PubMed  Google Scholar 

  • Kowatch RA, Scheffer RE, Monroe E, Delgado S, Altaye M, Lagory D (2015) Placebo-controlled trial of valproic acid versus risperidone in children 3–7 years of age with bipolar I disorder. J Child Adolesc Psychopharmacol 25(4):306–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL (2008) Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2(1):25

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee ES, Vidal C, Findling RL (2018) A focused review on the treatment of pediatric patients with atypical antipsychotics. J Child Adolesc Psychopharmacol 28(9):582–605

    Article  PubMed  Google Scholar 

  • Lilly USA LLC (2017) Straterra [Product information]. Lilly, Indianapolis

    Google Scholar 

  • Loebel A, Brams M, Goldman RS, Silva R, Hernandez D, Deng L et al (2016) Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord 46(4):1153–1163

    Article  PubMed  Google Scholar 

  • March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH et al (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280(20):1752–1756

    Article  CAS  PubMed  Google Scholar 

  • March JS, Entusah AR, Rynn M, Albano AM, Tourian KA (2007a) A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 62(10):1149–1154

    Article  CAS  PubMed  Google Scholar 

  • March JS, Franklin ME, Leonard H, Garcia A, Moore P, Freeman J, Foa E (2007b) Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 61(3):344–347

    Article  PubMed  Google Scholar 

  • McClellan J (2018) Psychosis in children and adolescents. J Am Acad Child Adolesc Psychiatry 57(5):308–312

    Article  PubMed  Google Scholar 

  • McClellan J, Kowatch R, Findling RL (2007) Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 46(1):107–125

    Article  PubMed  Google Scholar 

  • Meighen KG (2007) Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol 17(1):121–127

    Article  PubMed  Google Scholar 

  • National Institute of Mental Health (2016) Attention-deficit/hyperactivity disorder. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml

  • Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP, CAT Study Team (2008) Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 47(2):180–188

    Article  PubMed  Google Scholar 

  • The Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292(16):1969

    Article  Google Scholar 

  • Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM et al (1999) A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 103(4):e43

    Article  CAS  PubMed  Google Scholar 

  • Richmond TK, Rosen DS (2005) The treatment of adolescent depression in the era of the black box warning. Curr Opin Pediatr 17(4):466–472

    Article  PubMed  Google Scholar 

  • Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G et al (2001) Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40(2):222–229

    Article  CAS  PubMed  Google Scholar 

  • Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG (2010) Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 20(6):463–471

    Article  PubMed  Google Scholar 

  • Roohafza H, Pourmoghaddas Z, Saneian H, Gholamrezaei A (2014) Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial. Neurogastroenterol Motil 26(11):1642–1650

    Article  CAS  PubMed  Google Scholar 

  • Rynn MA, Siqueland L, Rickels K (2001) Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 158(12):2008–2014

    Article  CAS  PubMed  Google Scholar 

  • Sallee FR, Lyne A, Wigal T, McGough JJ (2009) Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(3):215–226

    Article  PubMed  Google Scholar 

  • Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D (2015) Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry 54(2):126–137

    Article  PubMed  Google Scholar 

  • Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P et al (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63(7):721–730

    Article  CAS  PubMed  Google Scholar 

  • Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L et al (2008) Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165(11):1420–1431

    Article  PubMed  Google Scholar 

  • Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47(8):921–929

    Article  PubMed  Google Scholar 

  • Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209(5):385–392

    Article  PubMed  Google Scholar 

  • Skarphedinsson G, Compton S, Thomsen PH, Weidle B, Dahl K, Nissen JB et al (2015) Tics moderate sertraline, but not cognitive-behavior therapy response in pediatric obsessive-compulsive disorder patients who do not respond to cognitive-behavior therapy. J Child Adolesc Psychopharmacol 25(5):432–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR (2009) Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19(5):501–510

    Article  PubMed  PubMed Central  Google Scholar 

  • Stepanova E, Findling RL (2017) Psychopharmacology of bipolar disorders in children and adolescents. Pediatr Clin 64(6):1209–1222

    Google Scholar 

  • Stepanova E, Dowling S, Phelps M, Findling RL (2017) Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues Clin Neurosci 19(4):395

    Article  PubMed  PubMed Central  Google Scholar 

  • Stigler KA, Mullett JE, Erickson CA, Posey DJ, McDougle CJ (2012) Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl) 223(2):237–245

    Article  CAS  Google Scholar 

  • Storch EA, Bussing R, Small BJ, Geffken GR, McNamara JP, Rahman O et al (2013) Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive–compulsive disorder. Behav Res Ther 51(12):823–829

    Article  PubMed  PubMed Central  Google Scholar 

  • Strawn JR, Prakash A, Zhang Q, Pangallo BA, Stroud CE, Cai N, Findling RL (2015) A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 54(4):283–293

    Article  PubMed  Google Scholar 

  • Varigonda AL, Jakubovski E, Bloch MH (2016) Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 55(10):851–859

    Article  PubMed  PubMed Central  Google Scholar 

  • Von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hultén A (2006) A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 26(3):311–315

    Article  CAS  Google Scholar 

  • Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS et al (2003a) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 290(8):1033–1041

    Article  CAS  PubMed  Google Scholar 

  • Wagner KD, Cook EH, Chung H, Messig M (2003b) Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13(2, Supplement 1):53–60

    Article  Google Scholar 

  • Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE (2004) A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161(6):1079–1083

    Article  PubMed  Google Scholar 

  • Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K (2006a) A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45(3):280–288

    Article  PubMed  Google Scholar 

  • Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K et al (2006b) A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 163(7):1179–1186

    Article  PubMed  Google Scholar 

  • Wagner KD, Redden L, Kowatch RA, Wilens TE, Segal S, Chang K et al (2009) A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 48(5):519–532

    Article  PubMed  Google Scholar 

  • Walkup JT, Labellarte MJ, Riddle MA, Pine DS, Greenhill L, Klein R et al (2001) Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344(17):1279–1285

    Article  CAS  Google Scholar 

  • Watson HJ, Rees CS (2008) Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 49(5):489–498

    Article  PubMed  Google Scholar 

  • Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB (2018) Desvenlafaxine versus placebo in a fluoxetine-referenced study of children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 28(1):36–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • West AE, Weinstein SM, Celio CI, Henry D, Pavuluri MN (2011) Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. J Child Adolesc Psychopharmacol 21(6):545–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Disclosure

Dr. Findling receives or has received research support, acted as a consultant and/or served on a speaker’s bureau for Acadia, Aevi, Akili, Alcobra, Allergan, Amerex, American Academy of Child & Adolescent Psychiatry, American Psychiatric Press, Arbor, Bracket, Daiichi-Sankyo, Epharma Solutions, Forest, Genentech, Insys, Ironshore, KemPharm, Luminopia, Lundbeck, Merck, NIH, Neurim, Noven, Nuvelution, Otsuka, PCORI, Pfizer, Physicians Postgraduate Press, Receptor Life Sciences, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Syneurx, Teva, TouchPoint, Tris, and Validus.

Dr. Robb receives or has received research support, acted as a consultant and/or served on a DSMB for Allergan, AACAP, American Academy of Pediatrics, Bracket, North American Center for Continuing Medical Education/Psychiatric Congress, Lundbeck, Medgenics Neuroscience Education Institute, Neuronetics, NCATS, NICHD, NINDS, NIMH, Shire, Supernus, University of Cambridge, I-ACT. Dr. Robb has stock in her IRA in Eli Lilly, Glaxo Smith Kline, Johnson and Johnson, and Pfizer.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Children’s National Health System, Washington, DC, USA

    Gabrielle Sky Cardwell & Adelaide S. Robb

  2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Robert L. Findling

Authors
  1. Gabrielle Sky Cardwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Findling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adelaide S. Robb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adelaide S. Robb .

Editor information

Editors and Affiliations

  1. Hospital for Children and Adolescents Center of Paediatric Research Department of Women and Child Health, University of Leipzig, Leipzig, Germany

    Wieland Kiess

  2. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Department of Clinical Pharmacology, University Hospital Tüebingen, Tüebingen, Germany, Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Stuttgart, Germany

    Matthias Schwab

  3. Children’s Hospital, University of Basel Children’s Hospital, Basel, Switzerland

    Johannes van den Anker

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cardwell, G.S., Findling, R.L., Robb, A.S. (2019). Psychiatric Diseases in Children and Adolescents. In: Kiess, W., Schwab, M., van den Anker, J. (eds) Pediatric Pharmacotherapy . Handbook of Experimental Pharmacology, vol 261. Springer, Cham. https://doi.org/10.1007/164_2019_262

Download citation

Publish with us

Policies and ethics

Search

Navigation